ChemSpider 2D Image | Savolitinib | C17H15N9

Savolitinib

  • Molecular FormulaC17H15N9
  • Average mass345.361 Da
  • Monoisotopic mass345.145050 Da
  • ChemSpider ID34501055
  • defined stereocentres - 1 of 1 defined stereocentres


More details:






Validated by Experts, Validated by Users, Non-Validated, Removed by Users

1-[(1S)-1-(Imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin [German] [ACD/IUPAC Name]
1-[(1S)-1-(Imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine [ACD/IUPAC Name]
1-[(1S)-1-(Imidazo[1,2-a]pyridin-6-yl)éthyl]-6-(1-méthyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine [French] [ACD/IUPAC Name]
1313725-88-0 [RN]
1H-1,2,3-Triazolo[4,5-b]pyrazine, 1-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)- [ACD/Index Name]
2A2DA6857R
9935
savolitinib [French] [INN]
savolitinib [Spanish] [INN]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

AZD-6094 [DBID]
HMPL-504 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous
    • Bio Activity:

      c-Met/HGFR MedChem Express HY-15959
      Protein Tyrosine Kinase/RTK MedChem Express HY-15959
      Protein Tyrosine Kinase/RTK; MedChem Express HY-15959
      Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity. MedChem Express
      Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity.; IC50 value: 5 nM [1]; Target: ; Volitinib demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.Volitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. MedChem Express HY-15959
      Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity.;IC50 value: 5 nM [1];Target: Volitinib demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.Volitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers. MedChem Express HY-15959

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module

Density: 1.6±0.1 g/cm3
Boiling Point:
Vapour Pressure:
Enthalpy of Vaporization:
Flash Point:
Index of Refraction: 1.833
Molar Refractivity: 98.0±0.5 cm3
#H bond acceptors: 9
#H bond donors: 0
#Freely Rotating Bonds: 3
#Rule of 5 Violations: 0
ACD/LogP: 0.54
ACD/LogD (pH 5.5): 0.49
ACD/BCF (pH 5.5): 1.11
ACD/KOC (pH 5.5): 28.93
ACD/LogD (pH 7.4): 0.88
ACD/BCF (pH 7.4): 2.71
ACD/KOC (pH 7.4): 70.70
Polar Surface Area: 92 Å2
Polarizability: 38.8±0.5 10-24cm3
Surface Tension: 69.6±7.0 dyne/cm
Molar Volume: 222.5±7.0 cm3

Click to predict properties on the Chemicalize site





Feedback Form